Full Text View
Tabular View
No Study Results Posted
Related Studies
Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients With Paricalcitol in German and Austrian Clinical Practice (TOP)
This study is ongoing, but not recruiting participants.
Study NCT01083849   Information provided by AbbVie

First Received on February 25, 2010.   Last Updated on March 12, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Kidney Insufficiency
Secondary Hyperparathyroidism
Additional conditions recognized in this trial
Hyperparathyroidism
Hyperparathyroidism, Secondary
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency
Renal Insufficiency, Chronic
More general conditions related to this trial
Endocrine System Diseases
Parathyroid Diseases
Urologic Diseases
Interventions listed in this trial
Zemplar (paricalcitol)
Additional drug interventions recognized in this trial
Ergocalciferols
More general drug interventions related to this trial
Bone Density Conservation Agents
Growth Substances
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins
Sponsors listed in this trial
AbbVie (prior sponsor, Abbott)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services